Compare INSP & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | NEO |
|---|---|---|
| Founded | 2007 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2018 | 2008 |
| Metric | INSP | NEO |
|---|---|---|
| Price | $43.45 | $13.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 8 |
| Target Price | ★ $94.00 | $13.38 |
| AVG Volume (30 Days) | 822.0K | ★ 2.7M |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 179.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,050,000.00 | N/A |
| Revenue This Year | $8.02 | $10.63 |
| Revenue Next Year | $8.11 | $9.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 62.18 | N/A |
| 52 Week Low | $38.91 | $4.72 |
| 52 Week High | $147.03 | $13.74 |
| Indicator | INSP | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 49.99 | 77.68 |
| Support Level | $39.26 | $11.49 |
| Resistance Level | $44.75 | $13.74 |
| Average True Range (ATR) | 1.99 | 0.67 |
| MACD | 0.49 | 0.18 |
| Stochastic Oscillator | 71.25 | 95.17 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and All other countries wherein, it generates a majority of its revenue from the United States. Its segment revenues are derived from the sales of its product, the Inspire system, to hospitals and ambulatory surgery centers in the U.S. and in selected countries in Europe and the Asia Pacific region.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.